Audited Financial results (Standalone and Consolidated) for the quarter and year ended 31.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Samsrita Labs Limited reported a massive standalone net loss of Rs. 868.60 Lakhs for FY 2026 (vs. loss of Rs. 25.95 Lakhs in FY 2025). Consolidated loss was Rs. 816.05 Lakhs, slightly better due to Rs. 52.55 Lakhs share of profit from associates (Krisani Bio Sciences and Qrops Advisory). The company wrote off Rs. 2.09 crore in irrecoverable trade receivables from Mangala Savitri Bizcon Private Limited and Rs. 3.15 lakh in old sundry creditors during the year. Reserves and Surplus stand at negative Rs. 1,141.09 Lakhs indicating accumulated losses. Operating cash flow was deeply negative at Rs. 502.42 Lakhs. The company appointed new internal auditors (Tungala & Co.) for FY 2026-27 and plans to expand into pet and home care products. Auditors issued an unmodified opinion but included an Emphasis of Matter on the trade receivables write-off.
The company is in severe financial distress with large accumulated losses and negative operating cash flows. The substantial bad debt write-offs and persistent losses signal high risk for investors. The auditors' going concern assessment and negative reserves require close monitoring.